Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 3, 2001, Pages 317-321

  Guiso, G ^a   Caccia, S ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLORO PYRIDO[2,3][1,5]BENZOXAZEPINE FUMARATE; CLOZAPINE; JL 13; METHYLPIPERAZINOPYRIDOBENZOXAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OXAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STANDARD; ULTRAVIOLET RADIATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FUMARATES; INJECTIONS, INTRAPERITONEAL; MALE; OXAZEPINES; PIPERAZINES; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0035096815     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011775541     Document Type: Article

References (23)

1. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat
2. Tissue concentrations of clozapine and its metabolites in the rat
3. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics
4. Atypical antipsychotics. Part II: Adverse effects, drug interactions, and cost
5. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties
6. Biotransformation of post-clozapine antipsychotics. Pharmacological implications
7. The use of atypical antipsychotics in the management of schizophrenia
8. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes
9. 3[H]dopa in various regions of the brain
10. Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats
11. Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: Tests with subtype selective receptor ligands
12. 11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET)
13. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rat
14. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study
15. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: An in vivo microdialysis study
16. Adverse effects of antipsychotic agents. Do newer agents offer advantages?
17. Zotepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
18. Atypical antipsychotics: Are some more atypical than others?
19. The new generation of antipsychotic drugs
20. Drug distribution between blood and brain as a determinant of antipsychotic drug effects
21. Distribution of clozapine and desmethylclozapine between blood and brain in rats
22. Clozapine concentrations in brain regions: Relationship to dopamine metabolite increase